The net prices and clinical benefit of therapeutic alternatives will be critical starting points for the Centers for Medicare and Medicaid Services as it looks to craft initial offers for the first set of drugs selected for US government price negotiations.
CMS outlined the methodology for developing an initial offer in draft guidance released on 15 March. The guidance describes...